Skip to main content
MarketsReportedHighDevelopingFeatured
7.7

Akeso shares plunge 31.8% after FDA rejects ivonescimab application

The FDA rejected Akeso's cancer drug ivonescimab, citing lack of substantial evidence of effectiveness, causing a 31.8% share price drop. This is a major setback for a leading Chinese innovative drug, raising doubts about its global commercial prospects and potentially impacting the broader Chinese biotech sector's sentiment.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works

South China Morning Post3 days agoCN, USengCredibility 23%View source

Score Breakdown

Mosaic Score7.7
Model confidence0.9
Significance0.8
Source credibility0.2

Intelligence Tags

Locations

Hong Kong

Entities

United StatescountryChinacountry
Source

Related signals

8 found